# A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

> **NCT06860243** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy Participants

## Interventions

- **DRUG:** Opevesostat
- **DRUG:** Prednisone
- **DRUG:** Fludrocortisone acetate

## Key facts

- **NCT ID:** NCT06860243
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-13
- **Primary completion:** 2026-02-09
- **Final completion:** 2026-02-19
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06860243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06860243, "A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06860243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*